The Pharma Data

SEPTEMBER 23, 2020

We are committed to clinical trial transparency and to sharing information related to our study, including details of our study protocol.”. “We This pivotal milestone demonstrates our focused efforts toward a COVID-19 vaccine that are built on collaboration and deep commitment to a robust scientific process.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccine 69

Vaccine Vaccination Trials Immune Response 69

The Pharma Data

SEPTEMBER 23, 2020

We are committed to clinical trial transparency and to sharing information related to our study, including details of our study protocol.” “With our vaccine candidate now in our global Phase 3 trial, we are one step closer to finding a solution for COVID-19. PHASE 3 ENSEMBLE STUDY. Learn more at www.janssen.com.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccine Vaccination 40

Pfizer

JULY 26, 2022

Tell your vaccination provider about all of the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. The information contained in this release is as of July 27, 2022. IMPORTANT SAFETY INFORMATION . has a fever. has a bleeding disorder or are on a blood thinner. Pfizer Disclosure Notice.

Vaccine 111

Vaccine Vaccination Protein Immune Response 111

Pfizer

JULY 8, 2022

Favorable safety profile observed across more than 2,200 adolescents who participated in the clinical trial. Today’s approval is based on data from a Phase 3 clinical trial of 2,260 participants 12 through 15 years of age. The information contained in this release is as of July 8, 2022. have a fever.

FDA Approval 102

FDA Approval Vaccine Vaccination Clinical Trials 102

Pfizer

SEPTEMBER 28, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . The information contained in this release is as of September 28, 2022. . • receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. .

Vaccine 101

Vaccine Vaccination Medicine Clinical Trials 101

Druggist

NOVEMBER 6, 2020

The best evidence for or against the effectiveness of medicines comes from well designed clinical trials. Diphenhydramine is a first-generation antihistamine, which is used to in the symptomatic treatment of allergies but more commonly as over the counter temporary sleeping aid medicines. £4.39 Buy on Amazon Price incl.

Medicine 69

Medicine Containment Production Pharmacy 69

Pfizer

JULY 19, 2022

Tell your vaccination provider about all of the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. The information contained in this release is as of July 19, 2022. IMPORTANT SAFETY INFORMATION. has a fever. has a bleeding disorder or are on a blood thinner. Pfizer Disclosure Notice.

Vaccine 100

Vaccine Vaccination Medicine Clinical Trials 100

Pfizer

JULY 8, 2022

The Phase 1/2/3 trial has enrolled more than 10,000 children ages 6 months to under 12 years of age in the United States, Finland, Poland, Spain and Brazil from more than 90 clinical trial sites. The information contained in this release is as of July 8, 2022. has a fever. has bleeding disorder or is on a blood thinner.

Vaccine 81

Vaccine Vaccination Clinical Trials Clinical Trials 81

The Pharma Data

DECEMBER 21, 2020

Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. RESEARCH TRIANGLE PARK, N.C., Post-marketing commitments for RAPIVAB are ongoing.

RNA 52

RNA Clinical Trials Clinical Trials Trials 52

The Pharma Data

DECEMBER 23, 2020

24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .

Vaccine 52

Vaccine Vaccination Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

This vaccine has immense potential in eliminating shedding and hence containing the spread of the pandemic.”. COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S. UB-612 Fact Sheet: www.covaxx.com/vaccine.

Vaccine 52

Vaccine Vaccination Manufacturing Antibody 52

Druggist

JULY 5, 2020

Nasal sprays for the management of blocked nose in babies usually contain the hypertonic saline solution, which has a decongestion effect. A hypertonic solution contains higher concentration (amount) of salt than fluids found in the body. Calpol Saline Nasal Spray contains 0.9% Products discussed below can be used from birth.

Production 69

Production Containment Sales Branding 69

XTalks

JANUARY 27, 2021

The study was conducted in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). “As Both contain the N501Y mutation — which is a mutation found in other lineages as well — while B.1.3351

Vaccine 52

Vaccine Vaccination In-Vitro Protein 52

The Pharma Data

DECEMBER 8, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.

Vaccine 40

Vaccine Vaccination Manufacturing Containment 40

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. ” Findings from the Phase 1 Clinical Trial. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. W911QY-20-C-0100.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

NAVIGATOR and the PATHFINDER clinical trial program Building on the Phase 2b PATHWAY trial, the Phase 3 PATHFINDER program included two trials, NAVIGATOR and SOURCE. 4,5 The program includes additional planned mechanistic and long-term safety trials.

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

NOVEMBER 17, 2020

The Company is thereby partnering with leading academic institutions to explore and select the best SARS-CoV antigens incorporated into virosome particles, while optimizing the route of administration and thermostability of the vaccine, before moving into human clinical trials.

Vaccine 40

Vaccine Vaccination Containment Development 40

The Pharma Data

JANUARY 4, 2021

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. To learn more, visit www.modernatx.com. Forward Looking Statements.

Vaccine 40

Vaccine Vaccination Medicine Containment 40

The Pharma Data

DECEMBER 21, 2020

PATHFINDER Clinical Trial Program Building on the positive Phase 2b PATHWAY trial, the Phase 3 PATHFINDER program included two trials, the registrational NAVIGATOR study and SOURCE. 12-15 The program includes additional planned mechanistic and long-term safety trials.

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

JUNE 25, 2021

Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at HHS. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. PREVENT-19 is being conducted with support from the U.S.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

XTalks

MARCH 1, 2021

The regulator used to require that innovator pharmas provide efficacy data on reducing both signs and symptoms of dry eye in the same clinical trial, but this proved to be challenging. Dry eye disease truly is a chronic condition for which there is no cure, so the operative word, at least for now, is management.

Sales 119

Sales Drugs Life Science Containment 119

Pfizer

DECEMBER 8, 2022

Pfizer and BioNTech previously announced the start of a Phase 1 trial to examine the safety, tolerability, and immunogenicity of their combined influenza and COVID-19 candidate vaccine among healthy adults. . Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccine 81

Vaccine Vaccination Clinical Trials Clinical Trials 81

Pfizer

NOVEMBER 2, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

Bioengineer

JULY 20, 2021

The FDA approval is based on the results of ProDERM (ClinicalTrials.gov Identifier: NCT02728752), a pivotal randomized clinical trial and the first study to evaluate the long term efficacy and safety of intravenous immunoglobulin (IVIg) for adults with dermatomyositis. Octagam® 10% does not contain sucrose. residents.

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

Pharmaceutical Technology

AUGUST 5, 2022

According to GlobalData’s Pharma Intelligence Center, there are only six drugs in active development for CJD, of which only one has been in clinical trials. Since research needs to be done under containment conditions, samples cannot be moved across different facilities, he explains.

Drugs 299

Drugs Protein Vaccination Vaccine 299

XTalks

NOVEMBER 5, 2024

per unit, included 958,903 units, each containing one ordinary share and three warrants to purchase additional shares at an exercise price of $4.38 is advancing novel nasal spray-based hydrogels with two innovative platforms: Capture and Contain (C&C) and Trap and Target (T&T). Polyrizon Ltd., million in gross proceeds.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

The Pharma Data

JULY 6, 2021

variant Apreprint submitted by the Company today to bioRxiv contains a new analysis from blood samples obtained from a subset of participants (n=8) in the Phase 3 ENSEMBLE study. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S.,

Vaccine 52

Vaccine Vaccination Immune Response Antibody 52

The Pharma Data

NOVEMBER 30, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. W911QY-20-C-0100.

Vaccine 52

Vaccine Vaccination Medicine Clinical Trials 52

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. It worked in the favor of vaccine makers that X.BB.1.5 remains the dominant variant. Both influenza and SARS-CoV-2 have RNA as their genetic material.

Vaccine 105

Vaccine Vaccination RNA Manufacturing 105

The Pharma Data

JULY 8, 2021

A preprint submitted by the Company today to bioRxiv contains a new analysis from blood samples obtained from a subset of participants (n=8) in the Phase 3 ENSEMBLE study. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S.,

Vaccine 52

Vaccine Vaccination Immune Response Antibody 52

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 29, 2021

January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints.

Vaccine 40

Vaccine Vaccination Trials Development 40

The Pharma Data

DECEMBER 2, 2020

However, Pfizer said in a statement released Wednesday that it has developed special shipping containers that use dry ice to keep the vaccine cold. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cells. An FDA advisory panel is set to meet on Dec.

Vaccine 40

Vaccine Vaccination Nurses Containment 40

The Pharma Data

NOVEMBER 4, 2020

It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. Importantly, we can leverage the knowledge and experience gained from the tremendous progress made by our U.S.

Sales 40

Sales Production Marketing Cardiology 40

Pfizer

SEPTEMBER 16, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . COMIRNATY® (COVID-19 Vaccine, mRNA) INDICATION. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. have a fever.

Marketing 75

Marketing Vaccine Vaccination Clinical Trials 75